Related Experiment Videos
Acute Exacerbation of Pre-existing Cancer-Related Pain: An Atypical Presentation of an Amivantamab-Induced
Ryutaro Yamaguchi1, Yosuke Tamura1, Yuki Asai1
1Department of Respiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Japan.
Abstract:
Cancer-related pain affects more than 70% of patients with advanced cancer and it is mediated by tumor invasion and inflammatory cytokine-induced neural sensitization. Anticancer therapies may transiently exacerbate pain through treatment-related inflammatory responses. Amivantamab, an EGFR-MET bispecific antibody approved for EGFR-mutated non-small cell lung cancer, commonly causes infusion-related reactions (IRRs), typically with flushing or respiratory symptoms. We report a case of a 70-year-old woman with EGFR-mutated lung adenocarcinoma who developed a reproducible, transient exacerbation of pre-existing cancer-related pain during initial amivantamab infusions without any systemic abnormalities or clear evidence of radiologic progression. This suggests that acute pain flare is an atypical manifestation of amivantamab-induced IRR.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists